Ipamorelin 10mg

Research applications

• Ghrelin receptor (GHS-R1a) binding and activation studies
• Growth hormone secretion research in animal models
• Receptor selectivity research versus earlier secretagogues
• Combination research alongside GHRH-receptor analogues

What the literature reports on Ipamorelin

Ipamorelin was developed as part of a research programme seeking growth hormone secretagogues with improved receptor selectivity relative to earlier compounds such as GHRP-6. Its pentapeptide structure incorporates the non-standard residue alpha-aminoisobutyric acid (Aib) and two D-amino acids, modifications documented in the original medicinal chemistry literature as conferring both receptor selectivity and resistance to enzymatic degradation.

Receptor selectivity research

Comparative pharmacology studies have reported that Ipamorelin selectively activates the ghrelin receptor without meaningfully stimulating cortisol or prolactin release, a selectivity profile distinguishing it from earlier growth hormone secretagogues. This selectivity has made Ipamorelin a preferred tool compound in research designed to isolate growth-hormone-axis signalling from broader hypothalamic-pituitary-adrenal activation.

Growth hormone secretion studies

Animal studies have reported dose-dependent growth hormone release following Ipamorelin administration, with pulsatile secretion patterns studied in the context of normal physiological growth hormone rhythms. This research has been used to characterise Ipamorelin's pharmacodynamic profile relative to endogenous ghrelin.

Combination research

Because Ipamorelin acts through the ghrelin receptor while GHRH analogues such as CJC-1295 act through a distinct receptor system, researchers frequently study the two compounds together, as covered in the CJC-1295 + Ipamorelin blend listing, to examine convergent effects on somatotroph cell signalling.

Structure-activity research

The pentapeptide design of Ipamorelin, including its non-standard Aib residue and two D-amino acid substitutions, has been studied as a case example in medicinal chemistry literature examining how minimal peptide scaffolds can achieve receptor selectivity, a research theme relevant to the broader design of ghrelin-receptor agonist compounds.

Metabolic research context

Because ghrelin receptor signalling is also implicated in appetite and energy balance research, some studies have examined secondary metabolic parameters alongside growth hormone measurements following Ipamorelin administration in animal models, extending Ipamorelin research beyond the growth-hormone axis into broader metabolic signalling literature.

Laboratory handling

Ipamorelin should be stored as lyophilised powder at -20°C, protected from light and moisture, until reconstitution. Reconstitution follows standard peptide practice: diluent introduced slowly along the vial wall, followed by gentle mixing.

• Lyophilised powder: store at -20°C, protected from light, until reconstitution.
• Reconstitution: introduce diluent slowly along the vial wall; mix gently, do not shake.
• Post-reconstitution: 2-8°C for short-term laboratory use; avoid repeated freeze-thaw cycles.
• Each batch ships with a certificate of analysis confirming ≥99% purity by HPLC and identity by mass spectrometry.

See the peptide reconstitution and storage guide for a full protocol reference. This product is intended for laboratory research use only.